The role of pathology in predicting immunotherapy response in urogenital tumors

ÖZLÜK M. Y.

Turk Onkoloji Dergisi, cilt.35, sa.4, ss.492-496, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5505/tjo.2020.2328
  • Dergi Adı: Turk Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.492-496
  • Anahtar Kelimeler: Cancer, Genitourinary, Immunotherapy, Pathology, PD-L1
  • İstanbul Üniversitesi Adresli: Evet

Özet

© 2020, Istanbul Tip Fakultesi. All rights reserved.Immune checkpoint inhibitors (ICI) are recently introduced in the management of various cancers. There are three main immunotargets as follows: Cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1). These three targets are under investigation for therapeutic, predictive and prognostic purposes in genitourinary cancers. There is a need for predictive biomarkers of immunotherapy to optimize treatment, to limit side-effects and to reduce the costs of therapy. This review focuses on the role of pathologic applications in the selection of patients with genitourinary cancer who are potentially responsive to immunotherapy. PD-L1 expression by im-munohistochemistry, tumor mutation burden and microsatellite instability status are mainly discussed.